• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与 CAPS 自身炎症相关的 NLRP3 功能获得性突变体的功能多样性。

Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation.

机构信息

CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University , Shanghai, China.

出版信息

J Exp Med. 2024 May 6;221(5). doi: 10.1084/jem.20231200. Epub 2024 Mar 26.

DOI:10.1084/jem.20231200
PMID:38530241
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10966137/
Abstract

NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development.

摘要

NLRP3 相关性自身炎症性疾病是一组由 NLRP3 获得性功能突变引起的异质性单基因疾病。尽管有有效的抗 IL-1 治疗,但大多数 NLRP3 变体的功能特征分析不佳,尽管有有效的抗 IL-1 治疗。此外,虽然 NLRP3 受到启动和激活信号的控制,但仅在对启动的反应中研究了获得性功能。在这里,我们在体外对 34 种 NLRP3 变体进行了特征描述,评估了它们在诱导、启动和/或激活信号下的活性,以及它们对四种抑制剂的敏感性。我们强调了获得性功能突变体的功能多样性,并根据控制其激活的信号描述了四个组,部分与症状严重程度相关。我们确定了一组新的 NLRP3 突变体,它们无需启动即可响应激活信号,与频繁误诊有关。我们的研究结果确定了控制炎症小体活性和抑制剂敏感性的关键 NLRP3 残基,以及具有更广泛疗效的拮抗机制,可为治疗策略提供新的见解。它们为 NLRP3 激活提供了新的见解,为 NLRP3-AID 异质性的解释机制提供了新的见解,并为 NLRP3-AID 的诊断和药物开发提供了原始工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/940e5db88ded/JEM_20231200_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/abdf0cb2570a/JEM_20231200_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/6b8a02b9f333/JEM_20231200_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/833aa350bfdc/JEM_20231200_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/c958760f76b1/JEM_20231200_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/075119b4e37c/JEM_20231200_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/a55b45cf62d1/JEM_20231200_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/3b38081df6fa/JEM_20231200_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/a17210ff1815/JEM_20231200_FigS5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/e7c39079000f/JEM_20231200_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/2d6f7ff5bebf/JEM_20231200_FigS6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/413d2b603b5d/JEM_20231200_FigS7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/df19dbcf849b/JEM_20231200_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/940e5db88ded/JEM_20231200_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/abdf0cb2570a/JEM_20231200_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/6b8a02b9f333/JEM_20231200_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/833aa350bfdc/JEM_20231200_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/c958760f76b1/JEM_20231200_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/075119b4e37c/JEM_20231200_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/a55b45cf62d1/JEM_20231200_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/3b38081df6fa/JEM_20231200_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/a17210ff1815/JEM_20231200_FigS5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/e7c39079000f/JEM_20231200_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/2d6f7ff5bebf/JEM_20231200_FigS6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/413d2b603b5d/JEM_20231200_FigS7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/df19dbcf849b/JEM_20231200_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfca/10966137/940e5db88ded/JEM_20231200_Fig6.jpg

相似文献

1
Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation.与 CAPS 自身炎症相关的 NLRP3 功能获得性突变体的功能多样性。
J Exp Med. 2024 May 6;221(5). doi: 10.1084/jem.20231200. Epub 2024 Mar 26.
2
NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies.NLRP3 炎性小体与 NLRP3 相关自身炎症性疾病:从 cryopyrin 的功能到靶向治疗。
Front Immunol. 2022 Oct 6;13:1007705. doi: 10.3389/fimmu.2022.1007705. eCollection 2022.
3
NLRP3 leucine-rich repeats control induced and spontaneous inflammasome activation in cryopyrin-associated periodic syndrome.NLRP3富含亮氨酸的重复序列控制与冷吡啉相关周期性综合征中诱导性和自发性炎性小体激活。
J Allergy Clin Immunol. 2023 Jan;151(1):222-232.e9. doi: 10.1016/j.jaci.2022.08.019. Epub 2022 Sep 6.
4
Engineered Pigs Carrying a Gain-of-Function NLRP3 Homozygous Mutation Can Survive to Adulthood and Accurately Recapitulate Human Systemic Spontaneous Inflammatory Responses.携带功能获得性 NLRP3 纯合突变的工程化猪可以存活至成年,并能准确重现人类全身性自发性炎症反应。
J Immunol. 2020 Nov 1;205(9):2532-2544. doi: 10.4049/jimmunol.1901468. Epub 2020 Sep 21.
5
Increased Prevalence of Q703K Variant Among Patients With Autoinflammatory Diseases: An International Multicentric Study.自身炎症性疾病患者中 Q703K 变异体的患病率增加:一项国际多中心研究。
Front Immunol. 2020 May 14;11:877. doi: 10.3389/fimmu.2020.00877. eCollection 2020.
6
Gain-of-function CEBPE mutation causes noncanonical autoinflammatory inflammasomopathy.CEBPE 功能获得性突变导致非典型自身炎症性炎症小体病。
J Allergy Clin Immunol. 2019 Nov;144(5):1364-1376. doi: 10.1016/j.jaci.2019.06.003. Epub 2019 Jun 13.
7
Gain of function mutation and inflammasome driven diseases in human and mouse models.功能获得性突变与炎症小体驱动的人类和小鼠模型疾病。
J Autoimmun. 2018 Jul;91:13-22. doi: 10.1016/j.jaut.2018.03.002. Epub 2018 Mar 30.
8
MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.MCC950/CRID3 能够强烈靶向野生型 NLRP3 的 NACHT 结构域,但不能靶向与疾病相关的突变体,从而抑制炎症小体。
PLoS Biol. 2019 Sep 16;17(9):e3000354. doi: 10.1371/journal.pbio.3000354. eCollection 2019 Sep.
9
Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β production.致病性 NLRP3 突变体形成组成性激活的炎症小体,导致 IL-1β 产生的免疫代谢限制。
Nat Commun. 2024 Feb 6;15(1):1096. doi: 10.1038/s41467-024-44990-0.
10
A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants.一种功能性炎性小体激活检测方法可区分携带致病性NLRP3突变的患者和具有低外显率变异的有症状患者。
Clin Immunol. 2015 Mar;157(1):56-64. doi: 10.1016/j.clim.2015.01.003. Epub 2015 Jan 14.

引用本文的文献

1
Adult onset cryopyrin-associated periodic syndrome due to germline missense mutation in in a previously healthy middle-aged woman.一名既往健康的中年女性因种系错义突变导致成人起病的冷吡啉相关周期性综合征 。
Front Immunol. 2025 Aug 25;16:1652177. doi: 10.3389/fimmu.2025.1652177. eCollection 2025.
2
Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action.发现具有新型作用机制的强效且选择性的人NLRP3抑制剂。
J Exp Med. 2025 Nov 3;222(11). doi: 10.1084/jem.20242403. Epub 2025 Sep 2.
3
The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets.

本文引用的文献

1
Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype.位于 NLRP3 LRR 结构域 861 位的致病性变异体导致依赖补体激活的非典型 CAPS 表型。
J Allergy Clin Immunol. 2023 Nov;152(5):1303-1311.e1. doi: 10.1016/j.jaci.2023.07.006. Epub 2023 Jul 26.
2
Distinct changes in endosomal composition promote NLRP3 inflammasome activation.内体组成的明显变化促进 NLRP3 炎性体的激活。
Nat Immunol. 2023 Jan;24(1):30-41. doi: 10.1038/s41590-022-01355-3. Epub 2022 Nov 28.
3
Cryo-EM structures of the active NLRP3 inflammasome disc.
NLRP3炎性小体从周期性发热到治疗靶点的作用扩展
Nat Immunol. 2025 Aug 18. doi: 10.1038/s41590-025-02230-7.
4
Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome in Children-From Pathogenesis to Treatment Strategies: A Comprehensive Review.儿童周期性发热、口疮性口炎、咽炎和颈淋巴结炎(PFAPA)综合征——从发病机制到治疗策略:综述
Paediatr Drugs. 2025 Jul 9. doi: 10.1007/s40272-025-00699-1.
5
Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly.由膜或蛋白质支架诱导的NLRP3聚集促进炎性小体组装。
Nat Commun. 2025 May 27;16(1):4887. doi: 10.1038/s41467-025-60277-4.
6
4-octyl itaconate reduces human NLRP3 inflammasome constitutive activation with the cryopyrin-associated periodic syndrome p.R262W, p.D305N and p.T350M variants.衣康酸4-辛酯可降低与冷吡啉相关周期性综合征的p.R262W、p.D305N和p.T350M变体相关的人类NLRP3炎性小体的组成性激活。
Cell Mol Life Sci. 2025 May 23;82(1):209. doi: 10.1007/s00018-025-05699-5.
7
Caspases: structural and molecular mechanisms and functions in cell death, innate immunity, and disease.半胱天冬酶:细胞死亡、固有免疫及疾病中的结构、分子机制与功能
Cell Discov. 2025 May 5;11(1):42. doi: 10.1038/s41421-025-00791-3.
8
Functional analysis of NLRP3 variants provides insight into inflammasome regulation.NLRP3变异体的功能分析为炎性小体调控提供了深入见解。
Nat Immunol. 2025 Mar;26(3):337-339. doi: 10.1038/s41590-025-02093-y.
9
Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants.通过疾病相关变体的功能分析阐明NLRP3激活和抑制的机制。
Nat Immunol. 2025 Mar;26(3):511-523. doi: 10.1038/s41590-025-02088-9. Epub 2025 Feb 10.
10
Navigating from cellular phenotypic screen to clinical candidate: selective targeting of the NLRP3 inflammasome.从细胞表型筛选到临床候选药物的探索:NLRP3炎性小体的选择性靶向作用
EMBO Mol Med. 2025 Jan;17(1):54-84. doi: 10.1038/s44321-024-00181-4. Epub 2024 Dec 9.
NLRP3 炎性小体活性盘的冷冻电镜结构。
Nature. 2023 Jan;613(7944):595-600. doi: 10.1038/s41586-022-05570-8. Epub 2022 Nov 28.
4
ATP-binding and hydrolysis of human NLRP3.人源 NLRP3 的 ATP 结合和水解。
Commun Biol. 2022 Nov 3;5(1):1176. doi: 10.1038/s42003-022-04120-2.
5
Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3.MCC950/CRID3对冷吡啉相关周期性综合征(CAPS)相关突变NLRP3炎性小体的有效体外抑制作用
Rheumatology (Oxford). 2022 Oct 6;61(10):e299-e313. doi: 10.1093/rheumatology/keac273.
6
Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation.寡聚化介导的 NLRP3 炎症小体激活调控的结构基础。
Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2121353119. doi: 10.1073/pnas.2121353119. Epub 2022 Mar 7.
7
Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3.NLRP3 十聚体与细胞因子释放抑制剂 CRID3 结合的结构。
Nature. 2022 Apr;604(7904):184-189. doi: 10.1038/s41586-022-04467-w. Epub 2022 Feb 3.
8
NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation.全长小鼠 NLRP3 结构揭示 NLRP3 小体控制通路激活。
Cell. 2021 Dec 22;184(26):6299-6312.e22. doi: 10.1016/j.cell.2021.11.011. Epub 2021 Dec 2.
9
Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition.含抑制剂的NLRP3 NACHT结构域晶体结构揭示炎性小体抑制机制
J Mol Biol. 2021 Dec 3;433(24):167309. doi: 10.1016/j.jmb.2021.167309. Epub 2021 Oct 20.
10
NLRP3 phosphorylation in its LRR domain critically regulates inflammasome assembly.NLRP3 在其 LRR 结构域中的磷酸化对于炎症小体的组装至关重要。
Nat Commun. 2021 Oct 6;12(1):5862. doi: 10.1038/s41467-021-26142-w.